BeiGene Ltd ADR Stock
Price
Target price
€141.00
€141.00
-2.080%
-3.0
-2.080%
€241.54
24.05.24 / Tradegate
WKN: A1437N / Symbol: BGNE / Name: BeiGene / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
BeiGene Ltd ADR Stock
A loss of -2.080% shows a downward development for BeiGene Ltd ADR.
We see a rather positive sentiment for BeiGene Ltd ADR with 9 Buy predictions and 1 Sell predictions.
With a target price of 241 € there is a hugely positive potential of 70.92% for BeiGene Ltd ADR compared to the current price of 141.0 €.
So far the community has only identified positive things for BeiGene Ltd ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of BeiGene Ltd ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of BeiGene Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| BeiGene Ltd ADR | -2.080% | -10.759% | 8.462% | -35.909% | -14.545% | -50.000% | - |
| Ardelyx Inc. | -10.570% | -13.495% | 3.392% | 89.573% | 7.578% | 9.088% | - |
| Evolus Inc | -5.830% | -8.130% | 6.604% | 32.164% | 24.862% | 51.678% | - |
| Salarius Pharmaceuticals Inc. | 5.580% | 0.971% | -2.804% | -69.412% | -25.045% | -98.384% | -99.993% |
Comments
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $236.00 to $254.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $184.00 to $186.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat